Filtered By:
Source: Canadian Journal of Cardiology
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 265 results found since Jan 2013.
Response to Letter to the Editor re “Elevated Incidence of Atrial Fibrillation and Stroke in Patients with Atrial Flutter – A Population-Based Study”
Publication date: Available online 15 June 2018Source: Canadian Journal of CardiologyAuthor(s): Lorne J. Gula, Damian P. Redfearn, Krista B. Jenkyn, Britney Allen, Allan C. Skanes, Peter Leong-Sit, Salimah Z. Shariff
Source: Canadian Journal of Cardiology - July 5, 2018 Category: Cardiology Source Type: research
Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran
Publication date: Available online 5 June 2018Source: Canadian Journal of CardiologyAuthor(s): Jeffrey Weitz, Karen M. Earl, Kori Leblanc, William Semchuk, Fakhreddin JamaliAbstractDabigatran is widely used for stroke prevention in atrial fibrillation. Dabigatran is no longer patent protected in Canada and 2 generic formulations were recently approved by Health Canada. Branded dabigatran utilizes a complex formulation to maintain the acidic microenvironment required for maximal absorption. Consequently, food does not influence its bioavailability and the efficacy and safety of dabigatran are similar with or without concomi...
Source: Canadian Journal of Cardiology - July 5, 2018 Category: Cardiology Source Type: research
Incident Atrial Fibrillation and Stroke in Patients With Atrial Flutter
Publication date: June 2018Source: Canadian Journal of Cardiology, Volume 34, Issue 6Author(s): Jorge A. Wong, Jeff S. Healey
Source: Canadian Journal of Cardiology - July 5, 2018 Category: Cardiology Source Type: research
Vascular Plugging for the Enlarging Pulmonary Arteriovenous Malformation in a Patient With Idiopathic Pulmonary Artery Hypertension
We report on a lady with PAVM and idiopathic pulmonary artery hypertension who, within 2 years of diagnosis, had an ischemic stroke, PAVM enlargement from 20 × 20 × 30 mm to 30x × 40 × 40 mm and oximetry decrease to 90%. Transcatheter occlusion of PAVM with a vascular plug was successful. A year later, she had no flow via the PAVM and systemic oximetry improved to 97%, but pulmonary vascular resistance increased to 1.5-fold of baseline.RésuméLa coexistence de l’hypertension artérielle pulmonaire idiopathique et d’une malformation artérioveineuse pulmonaire (MAVP) s’avère problématique, car même si la M...
Source: Canadian Journal of Cardiology - July 5, 2018 Category: Cardiology Source Type: research
Factors Influencing Oral Anticoagulation Prescription for Patients Presenting to Emergency Departments With Atrial Fibrillation and Flutter
Publication date: June 2018Source: Canadian Journal of Cardiology, Volume 34, Issue 6Author(s): Robert J.H. Miller, Derek S. Chew, Saman Rezazadeh, Sheila Klassen, Payam Pournazari, Eddy Lang, F. Russell QuinnAbstractAtrial fibrillation and atrial flutter (AF/AFL) are associated with an increased risk of stroke and systemic embolism. However, many patients are not started on guideline-recommended oral anticoagulation (OAC). We determined factors associated with initiation of OAC in eligible patients presenting to emergency departments. This retrospective cohort included patients with electrocardiogram (ECG)-documented AF/A...
Source: Canadian Journal of Cardiology - July 5, 2018 Category: Cardiology Source Type: research
Elevated Incidence of Atrial Fibrillation and Stroke in Patients With Atrial Flutter—A Population-Based Study
ConclusionsPatients with isolated atrial flutter develop AF and stroke at a higher rate than the general population. Catheter ablation reduces but does not eliminate future AF incidence and stroke risk and continued anticoagulation after successful atrial flutter ablation might therefore be warranted.RésuméIntroductionOn ignore le risque d’accident vasculaire cérébral (AVC) dû au flutter auriculaire et sa relation avec la progression de la fibrillation auriculaire (FA). La présente étude décrit l’incidence de la FA et de l'AVC chez les patients atteints de flutter auriculaire, et montre si l’ablation du flutt...
Source: Canadian Journal of Cardiology - July 5, 2018 Category: Cardiology Source Type: research
Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI)
ConclusionsDespite the short-term benefit and safety of an early invasive strategy in patients with STEMI receiving fibrinolysis, no statistically significant differences in MACE were observed over 7.8 years.RésuméContexteL’essai TRANSFER-AMI (Trial ofRoutineAngioplasty andStenting afterFibrinolysis toEnhanceReperfusion inAcuteMyocardialInfarction) a démontré la supériorité de la coronarographie précoce systématique (et d’une intervention coronarienne percutanée) comparativement au traitement standard après 30 jours chez les patients sous fibrinolytiques ayant subi un infarctus du myocarde (IM) avec sus-déca...
Source: Canadian Journal of Cardiology - July 5, 2018 Category: Cardiology Source Type: research
Automated 3-Dimensional Single-Beat Real-Time Volume Colour Flow Doppler Echocardiography in Children: A Validation Study of Right and Left Heart Flows
ConclusionsStroke volume determined using automated 3D-RT-VCFDE is feasible in children and in the right side of the heart. This technique potentially provides a noninvasive alternative to historically invasively acquired hemodynamic data and to cardiac magnetic resonance imaging.RésuméContexteUne nouvelle méthode de quantification du volume d’éjection en fonction du flux entrant mitral et du flux sortant aortique par la technique d’échocardiographie à flux Doppler couleur tridimensionnelle en temps réel automatisée (3D-RT-VCFDE) est plus précise que l’échocardiographie bidimensionnelle et présente .une ex...
Source: Canadian Journal of Cardiology - July 5, 2018 Category: Cardiology Source Type: research
Stroke Prevention for High-Risk Atrial Fibrillation in the Emergency Setting: Differences Between Canada and the United States
Publication date: July 2018 Source:Canadian Journal of Cardiology, Volume 34, Issue 7 Author(s): Bory Kea, Benjamin C. Sun, David R. Vinson
Source: Canadian Journal of Cardiology - June 27, 2018 Category: Cardiology Source Type: research
Reply to Kea et al.—Stroke Prevention for High-Risk Atrial Fibrillation in the Emergency Setting: Differences Between Canada and the US
Publication date: July 2018 Source:Canadian Journal of Cardiology, Volume 34, Issue 7 Author(s): Clare L. Atzema
Source: Canadian Journal of Cardiology - June 27, 2018 Category: Cardiology Source Type: research
Effects of Riociguat on Right Ventricular Remodeling in Chronic Thromboembolic Pulmonary Hypertension Patients: A Prospective Study
Conclusions Riociguat treatment was associated with increased RVSVI and trends for improvement in myocardial remodeling in CTEPH patients. A larger clinical study is warranted to observe the therapeutic benefits of riociguat on RV remodeling. Teaser Riociguat is an approved medical treatment for chronic thromboembolic pulmonary hypertension (CTEPH) patients. We studied the effects of riociguat treatment on right ventricular (RV) remodeling by means of magnetic resonance imaging (MRI) and positron emission tomography (PET). After 6 months of riociguat treatment in 6 CTEPH patients, RV function increased, fibrosis decreased ...
Source: Canadian Journal of Cardiology - June 26, 2018 Category: Cardiology Source Type: research
Response to Letter to the Editor re “Elevated Incidence of Atrial Fibrillation and Stroke in Patients with Atrial Flutter – A Population-Based Study”
Publication date: Available online 15 June 2018 Source:Canadian Journal of Cardiology Author(s): Lorne J. Gula, Damian P. Redfearn, Krista B. Jenkyn, Britney Allen, Allan C. Skanes, Peter Leong-Sit, Salimah Z. Shariff
Source: Canadian Journal of Cardiology - June 15, 2018 Category: Cardiology Source Type: research
Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran
Publication date: Available online 5 June 2018 Source:Canadian Journal of Cardiology Author(s): Jeffrey Weitz, Karen M. Earl, Kori Leblanc, William Semchuk, Fakhreddin Jamali Dabigatran is widely used for stroke prevention in atrial fibrillation. Dabigatran is no longer patent protected in Canada and 2 generic formulations were recently approved by Health Canada. Branded dabigatran utilizes a complex formulation to maintain the acidic microenvironment required for maximal absorption. Consequently, food does not influence its bioavailability and the efficacy and safety of dabigatran are similar with or without concomitant ...
Source: Canadian Journal of Cardiology - June 6, 2018 Category: Cardiology Source Type: research
Automated 3-Dimensional Single-Beat Real-Time Volume Colour Flow Doppler Echocardiography in Children: A Validation Study of Right and Left Heart Flows
Conclusions Stroke volume determined using automated 3D-RT-VCFDE is feasible in children and in the right side of the heart. This technique potentially provides a noninvasive alternative to historically invasively acquired hemodynamic data and to cardiac magnetic resonance imaging.
Source: Canadian Journal of Cardiology - May 26, 2018 Category: Cardiology Source Type: research
Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI)
Conclusions Despite the short-term benefit and safety of an early invasive strategy in patients with STEMI receiving fibrinolysis, no statistically significant differences in MACE were observed over 7.8 years.
Source: Canadian Journal of Cardiology - May 26, 2018 Category: Cardiology Source Type: research
